Miltenyi Biotec opens its first office in India, plans to invest in Cell & Gene Therapy Center of Excellence

New Delhi: Miltenyi Biotec is launching operations in India with its first office and investing to set up Miltenyi Innovation and Technology Center as CGT Centre of Excellence (COE) in Hyderabad, India.

This COE will be one of its first of its kind in India where scientists, researchers, industry experts, and clinicians can get classroom to hands-on trainings on cell and gene therapy (CGT) approaches right from proof-of-concept to pre-clinical / clinical development and commercialization. This COE also will provide Indian researchers, scientists and clinicians easier access to expertise, research, and manufacturing solutions.

Miltenyi Biotec is a global leader offering device, technology solutions, automated workflows, and CGT services for research and translational approaches as well as development for commercialization. This pivotal platform CliniMACS Prodigy® is uniquely positioned for end-to-end clinical development to manufacturing of CGT in an automated and functionally closed system for small-large scale manufacturing. Each year, more than 10,000 patients are treated with cell products using Miltenyi Biotec’s technologies.

The announcement was made after meeting of Revanth Reddy, Chief Minister, Telangana with Dr. Boris Stoffel, Board Member Miltenyi Biotec B.V. & Co. KG, and Managing Director Miltenyi Biotec, Dr. Toon Overstijns, Managing Director Miltenyi Biomedicine, and Annapurna Das, Managing Director India and Area Head India and Southeast Asia at BioAsia 2024.  Jayesh Ranjan IAS, Principal Secretary, Industries and Commerce Department and Shakthi M. Nagappan, Chief Executive Officer, Telangana Life Sciences, were also present during the meeting.

Chief Minister Reddy said that “I am delighted to note that Miltenyi Biotec has chosen Hyderabad to set-up their first Innovation and Technology Center. It gives me immense pleasure to note that this center will be an important node to help advance novel therapies within the scientific community and promises access to healthcare options for patients both in India but also worldwide. I welcome Miltenyi to the vibrant life sciences ecosystem of Telangana. I’m also happy to note that the center will offer training in cell and gene therapy to academia and industry, which aligns with our vision of skilling university.”

Dr Boris Stoffel, Miltenyi Biotec’s Managing Director, explains: “Miltenyi Biotec seeks to help bring new therapies to patients with high unmet medical need. Fostering knowledge exchange will be vital for CGT advancement by forging public-private partnerships like our recent MOU with BIRAC, DBT as CGT partner as well as collaborations between academic and industry partners. We have single-minded focus to drive accessibility, affordability and availability of CGT therapies by local development and manufacturing in India.”

Dr Stoffel also highlighted that the company intends to seek opportunities to catalyze development of chimeric antigen receptor (CAR) T cell clinical development and manufacturing, with the prospect of bringing centralized and point-of-care CAR T cell therapy to hospitals across India.